Akero Therapeutics, Inc. is a clinical-stage company dedicated to developing life-changing treatments for individuals suffering from serious metabolic diseases. Of particular focus is non-alcoholic steatohepatitis (NASH), a disease currently lacking in approved therapies. The organization's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 that offers defense against cellular stress while simultaneously regulating lipid, carbohydrate, and protein metabolism throughout the body. Currently, Akero is undertaking a Phase 2b clinical trial to evaluate the effectiveness of EFX for biopsy-confirmed NASH patients. Founded in 2017, previously operating under the name Pippin Pharmaceuticals, Inc., Akero has since become headquartered in South San Francisco, California.